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The incidence of, and risk factors for recurrent hospitalisation for pneumonia was investigated using 
data from Hospital Episode Statistics, linked to a UK primary care database. Within 90 days and 1 
year of follow-up, 1,733 (3.1%) and 5,064 (9.0%) developed recurrent pneumonia respectively. 
Smoking status at the time of hospitalisation with index pneumonia was associated with the risk of 
readmission with recurrent pneumonia within a year of discharge; current vs never smokers: aOR 
1.42,95% CI 1.32-1.53,p<0.001 and ex vs never smokers: aOR 1.24,95% CI 1.15-1.34,p<0.001. Other 






Preventing hospitalisation for pneumonia, especially during winter, is one of the priorities for 
respiratory disease in the NHS Long Term Plan, and for the British Thoracic Society. However, there 
are few studies related to recurrent hospitalisation for pneumonia and specifically no studies from 
the UK. Studies from the past two decades suggest recurrent hospitalisation for pneumonia occurs in 
9-17.6% of adults during a follow-up of 1-3 years following index admission with pneumonia.1–3 Non-
modifiable factors associated with increased risk of recurrent pneumonia include increasing age, 
impaired functional status, comorbidities and medications.4 Although there is a well-described dose-
dependent association of tobacco smoking with the development of pneumonia, the evidence in 
recurrent pneumonia is mixed.5–8  
The aims of this study were to determine the incidence of recurrent hospitalisation with pneumonia 
in England and the association of tobacco smoking, a potentially modifiable risk factor. 
Methods 
Hospitalisation data from Hospital Episode Statistics (HES, England), linked to the Clinical Practice 
Research Datalink (CPRD), and death registration data from Office for National Statistics (ONS), were 
used for this study. Ethical approval was provided by MHRA Independent Scientific Advisory 
Committee (ISAC) (study protocol number: 18_178A).  
Adults aged ≥18 years with the first episode of hospitalisation for pneumonia (index date) recorded 
in HES between 1 July 2002 and 30 June 2017 were included. The Public Health England 
‘epidemiological year’ definition of July- June was used as the unit of time to avoid the winter peak 
of pneumonia traversing two calendar years. Pneumonia was defined based on J12- J18 ICD-10 
codes recorded as the primary code for the first episode of hospitalisation. Recurrent pneumonia 
was defined as at least one episode of hospitalisation for pneumonia more than 30 days after index 
pneumonia. Patients were excluded if they had less than a year of time registered to the practice 
before admission, hospital-acquired pneumonia (admission for at least a day in the 10 days 
preceding the index admission) or readmission within 30 days of discharge. Patients were followed 
up from day one after the date of hospital discharge to either the date of admission for recurrent 
pneumonia, end of data collection (30 June 2017), date of transfer out of practice, date of last data 
collection for the practice or date of death, whichever came first. 
Read code lists for smoking status was developed using validated Read codes from previous 
research. The most recent documented smoking status (current, ex and never-smokers) in CPRD 
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before the index admission was used; ‘never-smokers’ with previous smoking history were recorded 
as ‘ex-smoker’.   
Descriptive statistics for the patient population were calculated. ‘Time to first recurrence’ was 
measured from day one after discharge from hospital to admission with recurrent pneumonia. The 
proportion of patients who developed recurrent pneumonia during a 5-year follow-up period was 
determined. Incidence rates (per 100 person-years) for recurrent pneumonia at different time 
intervals were determined; 90 days, 1 year and 5 years. Directed acyclic graph (DAG) was used to 
identify the minimum set of confounders to close the back-door paths, which included age, gender, 
deprivation, alcohol consumption and comorbidities (Supplementary File S1). Multiple imputation 
using chained equations was performed with 10 imputed datasets for smoking status (2.7% missing 
data) and alcohol consumption (15.0% missing data) (Supplementary File S2). Competing-risks 
regression analyses were conducted to determine the effect of tobacco smoking on hospitalisation 
for recurrent pneumonia with death as a competing event. Statistical analyses were performed using 
StataMP 15. 
Results 
The study cohort comprised 56,396 patients (Figure 1). Median age of the study cohort was 75 years 
(IQR 61-84 years) and 49.7% were male. 
Figure 1: Flowchart of the study population 
 
The median time to recurrence was 1.3 years (IQR 0.5-2.6 years). The incidence rates (per 100 
person-years) for recurrent pneumonia at 90 days, 1 year and 5 years were 13.6 (95% CI 13.0-14.2), 
11.1 (95% CI 10.8-11.4) and 7.10 (95% CI 6.97-7.23) correspondingly. Within 90 days and 1 year of 
follow-up, 1,733 (3.1%) and 5,064 (9.0%) developed recurrent pneumonia respectively, with 1,866 
(36.9%) patients hospitalised for more than one recurrence during the 1-year follow-up period. The 
30-day mortality for a recurrent pneumonia hospitalisation was 23.7% (n=3,011).  Over the period 
2002 to 2017, the proportion of recurrent pneumonia within one year of index admission increased 




Figure 2: Trend of recurrence of pneumonia within 31-90 days and 1 year of index pneumonia admission 
 
Note: 1-year recurrence refers to recurrence between 31-365 days after discharge for index pneumonia. 
Patients readmitted to hospital within 30 days of discharge were considered to be readmissions for the index 
episode, hence excluded. 
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Current smoking at index admission was independently associated with a 42% increased risk of 
recurrent pneumonia compared to having never smoked at any point in time (Table 1). This risk was 
halved in ex-smokers. Other factors independently associated with recurrent pneumonia were age, 
gender, deprivation and Charlson Comorbidity Index score. 
 
Table 1: Factors independently associated with recurrent pneumonia within a year of discharge: Competing-
risks regression (CRR) analysis with death as competing event 
 Total no of patients With recurrence Multivariate CRR p value 
 N n (%) sHR (95% CI) 
Number of patients 56396 5064     
Smoking status             
Never 18179 1274 (7.0) 1.00 Reference   
Ex 14512 1517 (10.5) 1.24 (1.15-1.34) <0.001 
Current 23678 2273 (9.6) 1.42 (1.32-1.53) <0.001 
Age             
18-49 8208 247 (3.0) 1.00 Reference   
50-64 8830 556 (6.3) 1.76 (1.51-2.05) <0.001 
65-74 10499 986 (9.4) 2.37 (2.05-2.75) <0.001 
75-84 15317 1692 (11.0) 2.78 (2.41-3.22) <0.001 
≥85 13542 1583 (11.7) 3.17 (2.73-3.67) <0.001 
Gender             
Male 28002 2719 (9.7) 1.00 Reference   
Female 28394 2345 (8.3) 0.85 (0.80-0.90) <0.001 
Alcohol status             
Non-drinker 14780 1451 (9.8) 1.00 Reference   
Former drinker 3319 381 (11.5) 1.08 (0.96-1.22) 0.176 
Occasional drinker 9047 854 (9.4) 0.95 (0.87-1.04) 0.237 
Moderate drinker 21468 1772 (8.3) 0.88 (0.82-0.95) 0.001 
Heavy drinker 7782 606 (7.8) 0.90 (0.81-1.01) 0.063 
IMD (patient-level)             
1 (least deprived) 10596 875 (8.3) 1.00 Reference   
2 11407 1023 (9.0) 1.06 (0.97-1.16) 0.195 
3 11909 1068 (9.0) 1.06 (0.97-1.16) 0.228 
4 11263 977 (8.7) 1.02 (0.93-1.12) 0.689 
5 (most deprived) 11171 1117 (10.0) 1.21 (1.10-1.32) <0.001 
Unknown 50 4 (8.0) 1.14 (0.45-2.89) 0.776 
Charlson Index            
0 13636 608 (4.5) 1.00 Reference   
1 12290 955 (7.8) 1.43 (1.29-1.59) <0.001 
2 9912 986 (9.9) 1.65 (1.48-1.84) <0.001 
3 7777 867 (11.1) 1.76 (1.58-1.97) <0.001 
4 5096 634 (12.4) 1.90 (1.69-2.14) <0.001 
≥5 7685 1014 (13.2) 2.00 (1.79-2.23) <0.001 
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Co-morbidities             
COPD 11798 1810 (15.3) 1.77 (1.65-1.89) <0.001 
Asthma 13347 1471 (11.0) 1.11 (1.03-1.18) 0.004 
*Chronic lung disease 896 106 (11.8) 1.56 (1.29-1.90) <0.001 
Congestive cardiac failure 5648 705 (12.5) 1.12 (1.02-1.23) 0.016 
Myocardial infarction 5268 614 (11.7) 1.03 (0.94-1.13) 0.496 
#Other cardiac diseases 23326 2344 (10.1) 1.05 (0.98-1.12) 0.149 
Malignancy 12397 1402 (11.3) 1.17 (1.10-1.25) <0.001 
Chronic renal disease 10974 1343 (12.2) 1.16 (1.09-1.24) <0.001 
Cerebrovascular disease 6377 768 (12.0) 1.05 (0.97-1.12) 0.228 
Diabetes mellitus 9390 996 (10.6) 1.14 (1.05-1.23) 0.001 
Cognitive impairment 5834 660 (11.3) 1.11 (1.02-1.21) 0.017 
Liver disease 531 53 (10.0) 1.24 (0.94-1.62) 0.128 
The 2015 English Index of Multiple Deprivation (IMD) was used as composite measure of material deprivation at the 
patient level.  
*Chronic lung disease excluding COPD and asthma 
# Other cardiac diseases excluding CCF and MI (e.g. hypertension, arrhythmias, valvular heart disease, conduction disorder 
of the heart, pericarditis, myocarditis) 
 
Two multivariate models were conducted: Model 1: all variables + Charlson Comorbidity Index (without individual 
comorbidities) and Model 2: all variables + individual comorbidities (without Charlson Comorbidity Index). Results are 
presented from Model 1, except for individual comorbidities from Model 2 as estimates for other variables in both models 
were similar. 
See Supplementary File S3 for factors associated with death within a year of discharge. 
Discussion  
To our knowledge, this is the first UK study to investigate the incidence of, and risk factors for 
recurrent hospitalisation for pneumonia. Current tobacco smoking status at index hospitalisation for 
pneumonia was independently associated with a higher risk of recurrent pneumonia.  
Studies from other countries having reported a range of incidences of recurrent pneumonia over 
different time-periods; 16.3% during a median follow-up of 475 days in Japan to 3.5% over an 11-
year period in Sweden.3,9 Marked differences in study methodology and healthcare system are likely 
to account for the variation, emphasising the importance of country-specific data. Our results are 
similar to data from Canada and Sweden; 2% recurrent pneumonia at 30 to 90 days from index 
admission, 17.6% recurrent pneumonia during a mean follow-up of under 3 years.2,7 Of note, we 
observed a 23.7% 30-day mortality for recurrent pneumonia, twice as high as 30-day inpatient 
mortality for index pneumonia based on BTS National Audit data.10 Similarly, Ishifuji et al. found that 
patients with recurrent pneumonia were almost three times more likely to have fatal outcomes 
during over a year’s follow-up compared to those without (HR 2.81, p<0.001).3 Our study also 
revealed a significant trend of increasing proportion of recurrent pneumonia between 2002- 2017. 
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Conversely, the BTS National Pneumonia Audit observed a decrease in mortality from index 
pneumonia over a ten-year period (2009 to 2019).10 Whether these trends in survival are related to 
the trends in pneumonia recurrence requires further investigation. 
Tobacco smoking is associated with an increased risk of developing community-acquired 
pneumonia.5 We extend this observation to an association between tobacco smoking and recurrent 
pneumonia. In a case-control study, El Sohl et al. reported that current smokers were twice more 
likely to be admitted with recurrent pneumonia compared to never smokers (HR=2.04, 95% CI 1.48-
2.82).6 Conversely, two prospective cohort studies (Canada, n=2709 and Spain, n=1556) did not find 
any association between smoking and recurrent pneumonia.7,8 These studies included younger 
patients (mean cohort ages 63 and 67 years).  
A key strength of this study is the large sample size representative of the English population with 
long-term follow-up. We considered all key variables in our DAG; vaccination status, dysphagia, 
severity of index pneumonia, cardiac complications after index pneumonia, functional status, 
oropharyngeal hygiene and medications were not listed in the minimal sufficient adjustment set of 
confounders to close the back-door paths. A potential weakness is that we cannot exclude the 
possibility of information bias from miscategorisation of the study exposure, confounders and 
outcomes. Missing data in smoking status and alcohol consumption were handled using multiple 
imputation. Another limitation is that data regarding the type of tobacco smoked were only available 
in about half of the patients, with most consuming cigarettes and few consuming cigars (<5%).  
In conclusion, our findings confirm a high and rising incidence of recurrent hospitalisation for 
pneumonia in England, and that current smoking status at index admission is associated with an 
increased risk of recurrent pneumonia. These findings support smoking cessation interventions as a 
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